TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01697566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
Study: NCT02753478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intracoronary infusion with saline on 22 and 4°C
Description: Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed.
Study: NCT03271164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FBPM10 System
Description: Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massages with vitamin E cream
Description: The other breast will be treated with wound massages with vitamin E cream.
Study: NCT02164344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
Study: NCT04464811

Intervention type: DIAGNOSTIC_TEST
Intervention: Furosemide stress test
Description: Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.

Intervention type: DIAGNOSTIC_TEST
Intervention: Furosemide stress test
Description: Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
Study: NCT04830943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
Study: NCT05211193

Intervention type: DEVICE
Intervention: eTNM delivered by URIS I nerve stimulation device
Description: eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
Study: NCT03107728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced orthotic brace
Description: Participants will use an advanced exoskeletal orthosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthotic brace
Description: Participants will use the standard of care orthosis
Study: NCT00243191

Intervention type: DRUG
Group type: OTHER
Intervention: imatinib mesylate
Description: 400 mg orally twice a day for 10 - 14 days
Study: NCT02558062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC ONE administration
Description: BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
Study: NCT02214069

Intervention type: DEVICE
Intervention: Record and transmit heart rhythm
Description: The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
Study: NCT02014662

Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric exercise
Description: Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
Study: NCT00693069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 300 mg on the day prior to angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel 600 mg on the day prior to angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
Study: NCT03388762

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GlucoSupreme™ Herbal
Description: This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
Study: NCT02993627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: 2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet therapy
Description: low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diet therapy
Description: low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
Study: NCT03011112

Intervention type: PROCEDURE
Intervention: Observational procedure
Description: All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
Study: NCT03676010

Intervention type: OTHER
Intervention: Solid tumours undergoing image-guided tumor ablation
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study: NCT01634724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a drug withdrawal during the long protocol
Description: GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
Study: NCT03011112

Intervention type: PROCEDURE
Intervention: Observational procedure
Description: All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.

Intervention type: PROCEDURE
Intervention: Observational procedure
Description: All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.

Intervention type: PROCEDURE
Intervention: Observational procedure
Description: All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
Study: NCT02974829

Intervention type: OTHER
Intervention: follow-up
Study: NCT03774797

Intervention type: OTHER
Intervention: Implementation Toolkit
Description: Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.

Intervention type: OTHER
Intervention: Implementation Toolkit
Description: Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
Study: NCT03971162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3+PRN
Description: intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6+PRN
Description: intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
Study: NCT02286596

Intervention type: DEVICE
Intervention: heparin-induced extracorporeal LDL precipitation
Description: Lipid apheresis for 3 hours
Study: NCT02317497

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Care Sedation (depth, level)
Description: As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care Sedation (depth, level)
Description: As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressors to maintain normal blood pressure values, if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressors to maintain normal blood pressure values, if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotherapeutics to lowr intracranial pressure, if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotherapeutics to lowr intracranial pressure, if needed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular stroke care to treat brain vessel occlusions, if needed
Study: NCT02951897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lobectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lobectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: segmentecomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy（pemetrexed+CISPLATIN）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy（pemetrexed+CISPLATIN）

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lymphadenectomy
Description: Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lymphadenectomy
Description: Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
Study: NCT00505934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily).~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily).
Study: NCT02317497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular stroke care to treat brain vessel occlusions, if needed
Study: NCT02951897

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lymphadenectomy
Description: Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CanPatrolTM to detect CTCs
Description: CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
Study: NCT02317497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive neurosurgery, if needed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive neurosurgery, if needed
Study: NCT02286596

Intervention type: DEVICE
Intervention: dextran sulfate adsorption
Description: Lipid apheresis for 3 hours
Study: NCT01425918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Enhancement Intervention
Description: The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Education
Description: Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
Study: NCT01418963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: single and multiple ascending oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single and multiple oral doses
Study: NCT04997226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS or tACS over the left DLPFC with adaptive memory game
Description: This intervention is described in arms 1 and 3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS or tACS over the left DLPFC with adaptive memory game
Description: This intervention is described in arms 1 and 3.
Study: NCT01340664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule taken orally twice daily with a meal for 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 150 mg
Description: 1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable daily dose of Metformin background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable daily dose of Metformin background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
Study: NCT02217813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 20 mg of current commercial formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 20 mg of new formulation
Study: NCT03138525

Intervention type: OTHER
Intervention: Blood sampling (MS)
Description: Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
Study: NCT01974804

Intervention type: PROCEDURE
Intervention: MRI
Study: NCT04173988

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: alloCART-19
Description: AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study: NCT01805154

Intervention type: DEVICE
Intervention: CRT Patients
Description: This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
Study: NCT04997226

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS or tACS over the left DLPFC with adaptive memory game
Description: This intervention is described in arms 2 and 4.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS or tACS over the left DLPFC with adaptive memory game
Description: This intervention is described in arms 2 and 4.